ERK-IN-1(compoundB)是RAF和ERK1/2的抑制剂，通过激活MAPK通路中的突变来治疗增生性疾病。这种活性与KRAS-突变型非小细胞肺癌、BRAF-突变型非小细胞肺癌、KRAS-突变型胰腺癌、KRAS-突变型结肠癌以及KRAS-突变型卵巢癌尤为相关。
货号:ajcx12908
CAS:1715025-32-3
分子式:C26H27BrF3N5O2
分子量：578.42
溶解度:Soluble in DMSO
纯度：98%
存储：Store at -20°C
库存：现货

Background:

ERK-IN-1 (compound B) is a RAF and ERK1/2 inhibitor in the treatment of a proliferative disease characterized by activating mutations in the MAPK pathway. The activity is particularly related to the treatment of KRAS-mutant NSCLC (non-small celllung cancer), BRAF-mutant NSCLC, KRAS-mutant pancreatic cancer, KRAS-mutant colorectal cancer (CRC) and KRAS-mutant ovanan cancer[1].

ERK-IN-1 (compound B) (50, 75 mg/kg, p.o., qd/q2d, 27 days) treatment significantly reduces the tumor volume in the Calu-6 human NSCLC subcutaneous tumor xenograft model in mice[1].|| Animal Model:|Calu-6 NSCLC xenograft tumor models in mice[1].|Dosage:|50, 75 mg/kg.|Administration:|Orally either daily (qd) or every other day (q2d) for 27 days.|Result:|Significantly reduced the tumor volume.

[1]. WO2018051306A1.